According to The Insight Partners market research study titled ‘NGS- Based RNA- Seq Market to 2027 – Global Analysis and Forecasts by Product & Services, Technology, Application and End User, the global NGS- based RNA- seq market was valued at US$ 1,240.87 Mn in 2017 and is estimated to reach US$ 7,984.90 Mn by 2027. The market is estimated to grow with a CAGR of 19.3% from 2018- 2027.The report highlights the trends prevalent in the global NGS- based RNA- seq market and the factors driving the market along with those that act as deterrents to its growth.
Download Sample PDF NGS-based RNA-seq Report Copy at: https://www.theinsightpartners.com/sample/TIPBT00002556/
Reduced cost of genome sequencing
The growth in the adoption of the next generation sequencing is rising, recently in few years, next generation sequencing price have reduced greatly. For instance, first whole human genome sequencing cost over US$ 3billion in 2001 and it took approximately 15 years for its completion. However, the costs for the same in recent years has reduces to US$1,000 and the process requires less number of days. The cost of sequencing was approximately US$ 3 billion, which dropped down to US$ 10 million in 2006 and as the development in the technologies as increased the prices of sequencing has decreased to US$ 5,000 in 2012. Major market players such as Illumina and Roche have introduced breakthrough technologies that have enabled in the cost and time reduction in the sequencing. Moreover, the increase in the service provider companies have entered the market and they are offering next generation sequencing in cheaper cost.
Advancements in sequencing technologies
In recent years the advancements in the next generation sequencing such as paired-end (PE) sequencing has led to produce twice the number of the reads for the same time during the library preparation. The technique involves sequencing at both the ends of DNA fragments in library and aligning the forward and reverse reads as read pairs. The techniques has also enabled sequences aligned more accurate read alignment and the ability to detect indels, which is not possible with single read data. The most recent and liked technique by the researchers is paired-end approach.
In addition, the advancement in the field of molecular biology has equally enhanced the sequencing procedures. Many industry players have come up with innovative NGS technology in last few years. For instance, Pacific Biosciences with Sequel, and Oxford Nanopore with PromethION. Additionally, three advances NSG systems that dominate the market includes Roche GS FLX (454), Illumina HiSeq 2000 (Solexa) and AB SOLiD (Agencourt).
Product & Services Insights
The NGS-based RNA sequencing market by product & services is segmented into sequencing platforms and consumables, sample preparation, sequencing services and data analysis, storage and management. In 2018, the sequencing platform & consumables segment held a largest market share of 38.3% of the NGS based RNA sequencing market, by product & services. This segment is also expected to dominate the market in 2027 owing to advantage which include quality of the sequence data, robustness and low noise while performing the sequence and others. Furthermore, the sample preparation segment is anticipated to witness the fastest growth rate during the forecast period, 2018 to 2027.
End User Insights
On the basis of end user, the NGS-based RNA sequencing market is segmented into research centers and academic & government institutes, hospitals & clinics, pharmaceutical & biotechnology companies, and others. In 2018, the research centers segment held a largest market share of 45.0% of the genomics market, by end user. This segment is also expected to dominate the market in 2027. However, the hospitals & clinics segment is anticipated to witness the fastest growth rate of 23.2% during the forecast period, 2018 to 2027. This higher growth rate of the segment owing to the providing the references for further researches are likely to propel the growth of the research centers and academic & government institutes segment in the coming future.
Product & service launch/update and partnerships, agreements & collaborations were observed as the most adopted strategy in global NGS-based RNA sequencing industry. Few of the strategic developments made by the players in the market are listed below;
2018: In January, Illumina, Inc. launched iSeq 100 Sequencing System that delivers exceptional data accuracy, at a low capital cost, making Illumina technology available to virtually any lab.
2018: In September, QIAGEN N.V. and NeuMoDx Molecular, Inc. entered into a partnership to commercialize two new fully integrated systems for automation of PCR (polymerase chain reaction) testing.
2017: In May, QIAGEN N.V. and Maccura Biotechnology Co., Ltd. entered into a partnership to accelerate local adaptations, development and commercialization of the GeneReader NGS System in the rapidly growing clinical and clinical research markets in China.
Global NGS- based RNA- seq market, based on the product & services is segmented into sample preparation, sequencing services, sequencing platform & consumables and data analysis, storage & management. The sample preparation segment is further bifurcated into method and workflow step segments. In 2017, sequencing platform & consumables segment held the largest share, by product& services. Additionally, the data analysis segment is anticipated to grow at a significant rate during the forecast period.
Global NGS- based RNA- seq market is expected to grow in the coming years, owing to the factors such as, reduced cost of genome sequencing, advancements in sequencing technology and next generation sequencing for cancer. However, the risks related to genetic data and high cost of NGS instruments is act as a restraint for this market. On the other hand, barcode scanning for long reads sequences likely to add novel opportunities for NGS- based RNA- seq market, in the coming years.
The major players operating in the NGS- based RNA- seq market include Illumina, Inc., Thermo Fisher Scientific Inc., Pacific Biosciences of California, Inc., Qaigen, F. Hoffmann- La Roche AG, Agilent Technologies, Inc., BGI, Oxford Nanopore Technologies, Perkinelmer, Inc. and Eurofins Scientific among others. The market players are focused towards bringing new and innovative product launches to sustain their position in the market. For instance, in October 2018, Agilent Technologies Inc. launched Agilent OnePGT, a genome- wide, next- generation sequencing (NGS) solution for preimplantation genetic testing (PGT).
The report segments the global NGS- based RNA- seq market as follows:
Global NGS- Based RNA- Seq Market – By Product & Services
Library Preparation & Target Enrichment
Fragmentation, End Repair & Size Selection
Sequencing Platform & Consumables
Data Analysis, Storage & Management
Global NGS- Based RNA- Seq Market – By Technology
Sequencing By Synthesis
Ion Semiconductor Sequencing
Single-Molecule Real-Time (SMRT) Sequencing
Global NGS- Based RNA- Seq Market – By Application
Global NGS-Based RNA-Seq Market – By End User
Hospitals & Clinics
Research Centers and Academic & Government Institutes
Biotechnology & Pharmaceutical Companies
Global NGS- Based RNA- Seq Market – By Geography
Asia Pacific (APAC)
Middle East & Africa (MEA)
South and Central America (SCAM)
Buy Complete NGS-based RNA-seq Report at: https://www.theinsightpartners.com/buy/TIPBT00002556/